(Stearyl, Norleucine17) VIP hybrid antagonizes VIP receptors on non-small cell lung cancer cells

Terry W. Moody; J. Leyton; T. Coelho; S. Jakowlew; K. Takahashi; F. Jameison; M. Koh; M. Fridkin; I. Gozes; M. Knight

doi:10.1016/S0024-3205(97)00771-6

(Stearyl, Norleucine¹⁷) VIP hybrid antagonizes VIP receptors on non-small cell lung cancer cells

Terry W. Moody^*, J. Leyton, T. Coelho, S. Jakowlew, K. Takahashi, F. Jameison, M. Koh, M. Fridkin, I. Gozes, M. Knight

^*Corresponding author for this work

Human Molecular Genetics Biochemistry

Research output: Contribution to journal › Article › peer-review

33 Scopus citations

Abstract

The effects of VIP receptor antagonists were investigated using non-small cell lung cancer (NSCLC) cells. By Northern blot and RT-PCR, VIP₁ receptors were detected on NSCLC cell line NCI-H1299. VIPhybrid,(N-Steary-Norleucine¹⁷) VIPhybrid ((SN)VIPhybrid) and PTC4495 inhibited ¹²⁵I-VIP binding to NCI-H1299 cells with IC₅₀ values of 500, 30 and 5000 nM respectively. (SN)VIPhybrid (1. μM) had no effect on basal cAMP but strongly inhibited the increase in cAMP caused by 10 nM VIP. The order of peptide potency to inhibit cAMP was (SN)VIPhybrid > VIPhybrid > PTC4495. (SN)VIPhybrid was more potent than VIPhybrid at inhibiting NCI-H1299 colony formation. Also, (SN)VIPhybrid was more potent than VIPhybrid at inhibiting NCI-H1299 xenograft formation in nude mice. These data suggest that (SN)VIPhybrid antagonizes VIP, receptors on NSCLC cells.

Original language	English
Pages (from-to)	1657-1666
Number of pages	10
Journal	Life Sciences
Volume	61
Issue number	17
DOIs	https://doi.org/10.1016/S0024-3205(97)00771-6
State	Published - 19 Sep 1997

Keywords

(S,N)
Cell proliferation
Non-small cell lung cancer
VIP hybrid
VIP receptor antagonists
cAMP

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/S0024-3205(97)00771-6

Cite this

@article{da94b8cd7fdd4e7d877026705194c1c6,

title = "(Stearyl, Norleucine17) VIP hybrid antagonizes VIP receptors on non-small cell lung cancer cells",

abstract = "The effects of VIP receptor antagonists were investigated using non-small cell lung cancer (NSCLC) cells. By Northern blot and RT-PCR, VIP1 receptors were detected on NSCLC cell line NCI-H1299. VIPhybrid,(N-Steary-Norleucine17) VIPhybrid ((SN)VIPhybrid) and PTC4495 inhibited 125I-VIP binding to NCI-H1299 cells with IC50 values of 500, 30 and 5000 nM respectively. (SN)VIPhybrid (1. μM) had no effect on basal cAMP but strongly inhibited the increase in cAMP caused by 10 nM VIP. The order of peptide potency to inhibit cAMP was (SN)VIPhybrid > VIPhybrid > PTC4495. (SN)VIPhybrid was more potent than VIPhybrid at inhibiting NCI-H1299 colony formation. Also, (SN)VIPhybrid was more potent than VIPhybrid at inhibiting NCI-H1299 xenograft formation in nude mice. These data suggest that (SN)VIPhybrid antagonizes VIP, receptors on NSCLC cells.",

keywords = "(S,N), Cell proliferation, Non-small cell lung cancer, VIP hybrid, VIP receptor antagonists, cAMP",

author = "Moody, {Terry W.} and J. Leyton and T. Coelho and S. Jakowlew and K. Takahashi and F. Jameison and M. Koh and M. Fridkin and I. Gozes and M. Knight",

year = "1997",

month = sep,

day = "19",

doi = "10.1016/S0024-3205(97)00771-6",

language = "אנגלית",

volume = "61",

pages = "1657--1666",

journal = "Life Sciences",

issn = "0024-3205",

publisher = "Elsevier Inc.",

number = "17",

}

TY - JOUR

T1 - (Stearyl, Norleucine17) VIP hybrid antagonizes VIP receptors on non-small cell lung cancer cells

AU - Moody, Terry W.

AU - Leyton, J.

AU - Coelho, T.

AU - Jakowlew, S.

AU - Takahashi, K.

AU - Jameison, F.

AU - Koh, M.

AU - Fridkin, M.

AU - Gozes, I.

AU - Knight, M.

PY - 1997/9/19

Y1 - 1997/9/19

N2 - The effects of VIP receptor antagonists were investigated using non-small cell lung cancer (NSCLC) cells. By Northern blot and RT-PCR, VIP1 receptors were detected on NSCLC cell line NCI-H1299. VIPhybrid,(N-Steary-Norleucine17) VIPhybrid ((SN)VIPhybrid) and PTC4495 inhibited 125I-VIP binding to NCI-H1299 cells with IC50 values of 500, 30 and 5000 nM respectively. (SN)VIPhybrid (1. μM) had no effect on basal cAMP but strongly inhibited the increase in cAMP caused by 10 nM VIP. The order of peptide potency to inhibit cAMP was (SN)VIPhybrid > VIPhybrid > PTC4495. (SN)VIPhybrid was more potent than VIPhybrid at inhibiting NCI-H1299 colony formation. Also, (SN)VIPhybrid was more potent than VIPhybrid at inhibiting NCI-H1299 xenograft formation in nude mice. These data suggest that (SN)VIPhybrid antagonizes VIP, receptors on NSCLC cells.

AB - The effects of VIP receptor antagonists were investigated using non-small cell lung cancer (NSCLC) cells. By Northern blot and RT-PCR, VIP1 receptors were detected on NSCLC cell line NCI-H1299. VIPhybrid,(N-Steary-Norleucine17) VIPhybrid ((SN)VIPhybrid) and PTC4495 inhibited 125I-VIP binding to NCI-H1299 cells with IC50 values of 500, 30 and 5000 nM respectively. (SN)VIPhybrid (1. μM) had no effect on basal cAMP but strongly inhibited the increase in cAMP caused by 10 nM VIP. The order of peptide potency to inhibit cAMP was (SN)VIPhybrid > VIPhybrid > PTC4495. (SN)VIPhybrid was more potent than VIPhybrid at inhibiting NCI-H1299 colony formation. Also, (SN)VIPhybrid was more potent than VIPhybrid at inhibiting NCI-H1299 xenograft formation in nude mice. These data suggest that (SN)VIPhybrid antagonizes VIP, receptors on NSCLC cells.

KW - (S,N)

KW - Cell proliferation

KW - Non-small cell lung cancer

KW - VIP hybrid

KW - VIP receptor antagonists

KW - cAMP

UR - http://www.scopus.com/inward/record.url?scp=0030613760&partnerID=8YFLogxK

U2 - 10.1016/S0024-3205(97)00771-6

DO - 10.1016/S0024-3205(97)00771-6

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???

AN - SCOPUS:0030613760

SN - 0024-3205

VL - 61

SP - 1657

EP - 1666

JO - Life Sciences

JF - Life Sciences

IS - 17

ER -